These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1100 related articles for article (PubMed ID: 16916931)

  • 1. A2A adenosine receptor protects tumors from antitumor T cells.
    Ohta A; Gorelik E; Prasad SJ; Ronchese F; Lukashev D; Wong MK; Huang X; Caldwell S; Liu K; Smith P; Chen JF; Jackson EK; Apasov S; Abrams S; Sitkovsky M
    Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13132-7. PubMed ID: 16916931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
    Sitkovsky MV; Kjaergaard J; Lukashev D; Ohta A
    Clin Cancer Res; 2008 Oct; 14(19):5947-52. PubMed ID: 18829471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments.
    Ohta A; Ohta A; Madasu M; Kini R; Subramanian M; Goel N; Sitkovsky M
    J Immunol; 2009 Nov; 183(9):5487-93. PubMed ID: 19843934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor.
    Eini H; Frishman V; Yulzari R; Kachko L; Lewis EC; Chaimovitz C; Douvdevani A
    Biochem Pharmacol; 2015 Nov; 98(1):110-8. PubMed ID: 26296573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
    Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
    Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of hypoxia and A2A adenosine receptors in liver tissue-protecting physiological anti-inflammatory pathway.
    Choukèr A; Thiel M; Lukashev D; Ward JM; Kaufmann I; Apasov S; Sitkovsky MV; Ohta A
    Mol Med; 2008; 14(3-4):116-23. PubMed ID: 18163162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
    Cekic C; Day YJ; Sag D; Linden J
    Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
    Young A; Ngiow SF; Gao Y; Patch AM; Barkauskas DS; Messaoudene M; Lin G; Coudert JD; Stannard KA; Zitvogel L; Degli-Esposti MA; Vivier E; Waddell N; Linden J; Huntington ND; Souza-Fonseca-Guimaraes F; Smyth MJ
    Cancer Res; 2018 Feb; 78(4):1003-1016. PubMed ID: 29229601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible.
    Ohta A; Madasu M; Subramanian M; Kini R; Jones G; Choukèr A; Ohta A; Sitkovsky M
    Int Immunol; 2014 Feb; 26(2):83-91. PubMed ID: 24150242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
    Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
    Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine Generated by Regulatory T Cells Induces CD8
    Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
    Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine-A2A Receptor Pathway in Cancer Immunotherapy.
    Sun C; Wang B; Hao S
    Front Immunol; 2022; 13():837230. PubMed ID: 35386701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
    Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
    Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular adenosine controls NKT-cell-dependent hepatitis induction.
    Subramanian M; Kini R; Madasu M; Ohta A; Nowak M; Exley M; Sitkovsky M; Ohta A
    Eur J Immunol; 2014 Apr; 44(4):1119-29. PubMed ID: 24448964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.
    Willingham SB; Ho PY; Hotson A; Hill C; Piccione EC; Hsieh J; Liu L; Buggy JJ; McCaffery I; Miller RA
    Cancer Immunol Res; 2018 Oct; 6(10):1136-1149. PubMed ID: 30131376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
    Hatfield SM; Sitkovsky M
    Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
    Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
    Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.